BrainPatrol: Revolutionizing Brain Cancer Treatment
Discover our solution
The technology
Combination of coated magnetic particles and an external magnetic navigation mechanism that travels through brain tissue to reach target cells – without passing through the bloodstream.
Through external magnetic control and advanced algorithms, we guide the particles directly to the affected area, where they perform one of several actions: destroying the cells through vibration, releasing drugs, or physically removing the cells.
This is an innovative platform that bypasses the BBB, offering new hope for a wide range of brain diseases – with minimal invasiveness and maximum precision.
The science behind it
We deliver coated magnetic particles using optional multiple access routes: the spinal cord, a dedicated port (Ommaya), a syringe, or through the nasal cavity.
The particles are guided by a controlled external magnetic field and targeted-frequency vibration – enabling precise arrival at the problematic site.
Thanks to our coating and algorithms, the particles bind exclusively to the tumor cell environment.
The particles perform one or a combination of the following actions:
• Vibration at a cell-lethal frequency
• Local drug release
• Extraction of the cancerous cell
Even after the procedure, selected particles can remain in the area to patrol – ready to detect newly emerging cancer cells that could trigger a recurrence and act immediately.
What makes us unique?
Navigation within brain tissue
Bypasses the blood-brain barrier (BBB)!
Targeted treatment using low and safe energy
Continuous monitoring for early detection of recurrence
Unique technology combining magnetic force, vibration, navigation, and drug delivery
Frequently Asked Questions
Most are cleared from the body. Some may remain for ongoing patrol, if medically needed.
ALONA treats the tumor physically and directly – without harming surrounding tissue and with no systemic side effects.
Our specialized coating and smart navigation ensure precise binding to tumor cells only.
Absolutely. In the future, it will also be applied to Alzheimer’s, Parkinson’s, infections, and more.
We’re approaching animal trials and are in an advanced preclinical stage, preparing for an FDA meeting.
Via targeted injection into the brain or spinal cord, a brain port (Ommaya), or through the nasal passage – depending on the specific case.